Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Genentech (NYSE:DNA) said a special committee of the company's board rejected an offer by Roche (SIX:ROG) to acquire the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury